Pregabalin: A review of its use in fibromyalgia

Drugs

Volumn 68, Issue 15, 2008, Pages 2205-2223

  Lyseng Williamson, Katherine A ^a   Siddiqui, M Asif A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis drug evaluations; Fibromyalgia; Pregabalin, general

Indexed keywords

ALCOHOL; ANTICONVULSIVE AGENT; CALCIUM CHANNEL; ETHINYLESTRADIOL PLUS NORETHISTERONE; FUROSEMIDE; GLIBENCLAMIDE; INSULIN; LORAZEPAM; METFORMIN; OXYCODONE; PLACEBO; PREGABALIN;

ANXIETY; ARTHRALGIA; ATTENTION DISTURBANCE; BALANCE DISORDER; BLURRED VISION; CHANNEL GATING; CLINICAL TRIAL; CONSTIPATION; CREATININE CLEARANCE; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; EUPHORIA; FATIGUE; FIBROMYALGIA; HEADACHE; HEALTH STATUS; HUMAN; INCREASED APPETITE; INFLUENZA; INSOMNIA; NAUSEA; NEUROMODULATION; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; REVIEW; SIDE EFFECT; SINUSITIS; SOMNOLENCE; WEIGHT GAIN; XEROSTOMIA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; ENDPOINT DETERMINATION; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HUMANS;

EID: 53549087538     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868150-00009     Document Type: Review

References (53)

1. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia. JAMA 2004 Nov 17; 292 (19): 2388-95
2. Rooks DS. Fibromyalgia treatment update. Curr Opin Rheumatol 2007 Mar; 19 (2): 111-7
3. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008 Apr; 67 (4): 536-41
4. Chakrabarty S, Zoorob R. Fibromyalgia. Am Fam Physician 2007 Jul 15; 76 (2): 247-54
5. American College of Rheumatology. Fibromyalgia [online]. Available from URL: http://www.rheumatology.org/public/ factsheets/fibromya_new.asp [Accessed 2008 Jun 18]
6. Clauw DJ. Fibromyalgia: update on mechanisms and management. JCR J Clin Rheumatol 2007; 13 (2): 102-9
7. Perrot S. Fibromyalgia syndrome: a relevant recent construction of an ancient condition? Curr Opin Support Palliat Care 2008; 2 (2): 122-7
8. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum 1990; 33 (2): 160-72
9. Wood PB, Holman AJ, Jones KD. Novel pharmacotherapy for fibromyalgia. Expert Opin Invest Drugs 2007; 16 (6): 829-41
10. Staud R. Treatment of fibromyalgia and its symptoms. Expert Opin Pharmacother 2007; 8 (11): 1629-42
11. Gur A, Oktayoglu P. Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: new concepts in treatment. Curr Pharm Des 2008; 14 (13): 1274-94
12. White KP, Harth M. Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep 2001; 5 (4): 320-9
13. Pfizer's Lyrica receives FDA approval for fibromyalgia based on expedited review [media release]. Available from URL: http://www.pfizer.com/news/ press_releases/pfizer_press_releases.jsp [Accessed 2008 May 30]
14. Medline Plus. Cymbalta approved for fibromyalgia [online]. Available from URL: http://www.nlm.nih.gov/medlineplus/ new/fullstory_65861.html [Accessed 2008 Jun 18]
15. Lyrica (pregabalin) capsules: US prescribing information. New York: Pfizer Inc., 2007 Jun
16. European Medicines Agency. Lyrica (pregabalin): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/Humans/EPAR/lyrica/lyrica.htm [Accessed 2008 May 30]
17. Frampton JE, Foster RH. Pregabalin in the treatment of postherpetic neuralgia. Drugs 2005; 65 (1): 111-8
18. Lauria-Horner BA, Pohl RB. Pregabalin: a new anxiolytic. Expert Opin Investig Drugs 2003; 12 (4): 663-72
19. Bryans JS, Wustrow DJ. 3-Substituted GABA analogs with central nervous system activity: a review. Med Res Rev 1999 Mar; 19 (2): 149-77
20. Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg 2007; 105 (6): 1805-15
21. 2- δ protein. J Med Chem 2005 Apr 7; 48 (7): 2294-307
22. 2δ ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007; 28 (2): 75-82
23. 2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Rev 2007; 73 (2): 173-50
24. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2005; 61 (3): 246-55
25. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45 Suppl. 6: 13-8
26. 2-δ-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A 2006 Nov 14; 103 (46): 17537-42
27. Beidler D, Kinsora J, El-Kattan A, et al. Pregabalin demonstrates activity in animal models of pain, sleep, and anxiety that reflect the symptoms and comorbidities associated with fibromyalgia [abstract no. 522]. Arthritis Rheum 2004 Sep; 50 (9 Suppl.): S250
28. Field MJ, Oles RJ, Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol 2001 Jan; 132 (1): 1-4
29. Kubota T, Fang J, Meltzer LT, et al. Pregabalin enhances nonrapid eye movement sleep. J Pharmacol Exp Ther 2001 Dec; 299 (3): 1095-105
30. Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl) 2005 Dec; 183 (2): 133-43
31. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005 Feb 1; 28 (2): 187-93
32. de Haas S, Otte A, de Weerd A, et al. Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy. J Clin Sleep Med 2007 Aug 15; 3 (5): 473-8
33. Busch JA, Strand JC, Posvar EL, et al. Pregabalin (CI-1008) single-dose pharmacokinetics and safety tolerance in healthy subjects after administration of pregabalin solution or capsule doses [abstract no. 2.108]. Epilepsia 1998; 39 Suppl. 6: 58
34. Corrigan BW, Pool WF, Posvar EL, et al. Metabolic disposition of pregabalin in healthy volunteers [abstract no. PI-68]. Clin Pharmacol Ther 2001 Feb; 69 (2): P18
35. Randinitis EJ, Posvar EL, Alvey CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003 Mar; 43 (3): 277-83
36. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005 Apr; 52 (4): 1264-73
37. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008 Mar; 35 (3): 502-14
38. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008 Sep; 9 (9): 792-805
39. Pauer L, Danneskiold-Samsoe B, Jesperson A, et al. Pregabalin for management of fibromyalgia (FM): a 14-week randomized, double-blind, placebo-controlled monotherapy trial (study A0081100) [abstract no. THU0382]. Ann Rheum Dis 2008; 67 Suppl. II: 256. Plus poster presented at the Congress of the European League Against Rheumatism; 2008 Jun 11-14; Paris
40. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008 Jun; 136 (3): 419-31
41. Florian H, Young Jr JP, Haig G, et al. Efficacy and safety of pregabalin as long-term treatment of pain associated with fibromyalgia: a 1-year, open-label study [abstract no. 1523]. Arthritis Rheum 2007 Sep 1; 56 (9 Suppl.): S602
42. Arnold L, Pauer L, Whalen E, et al. Pain changes in pregabalin-treated (Lyrica®) fibromyalgia patients associate with anxiety and depression changes [abstract no. 290]. J Pain 2008 Apr; 9 (4 Suppl. 2). Plus poster presented at the 27th Annual Scientific Meeting of the American Pain Society; 2008 May 8-10; Tampa (FL)
43. Arnold L, Leon T, Whalen E, et al. Treatment with pregabalin is associated with improvement in pain regardless of the presence of baseline symptoms of anxiety or depression: findings from 3 randomized clinical trials [abstract no. THU358]. Ann Rheum Dis 2008; 67 Suppl. II: 249. Plus poster presented at the Congress of the European League Against Rheumatism; 2008 Jun 11-14; Paris
44. Farrar JT, Young Jr JP, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on a 11-point numerical rating scale. Pain 2001; 94 (2): 149-58
45. Dunkl PR, Taylor AG, McConnell GG, et al. Responsiveness of fibromyalgia clinical trial outcome measures. J Rheumatol 2000; 27 (11): 2683-91
46. White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008; 50 (1): 13-24
47. Forseth KØ, Gran JT. Management of fibromyalgia: what are the best treatment choices? Drugs 2002; 62 (4): 577-92
48. Lawson K. Pharmacological treatments of fibromyalgia: do complex conditions need complex therapies? Drug Discov Today 2008 Apr; 13 (7-8): 333-40
49. Staud R, Price DD. Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: how study designs can affect placebo factors. Pain 2008 Jun; 136 (3): 232-4
50. Arnold LM, Crofford LJ, Martin SA, et al. The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med 2007; 8 (8): 633-8
51. Arnold LM, Pritchett YL, D'Souza DN, et al. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health (Larchmt) 2007 Oct; 16 (8): 1145-56
52. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008 Jun; 136 (3): 432-44
53. Calandre EP, Morillas-Arques P, Rodriguez-Lopez CM, et al. Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label, prospective trial. Pharmacopsychiatry 2007 Mar; 40 (2): 68-71